

## RUBRA MEDICAMENTS LIMITED

### Statement of Standalone Audited Financial Results for the Quarter and Year ended March 31, 2020

(Rs. in Lakhs)

Sr.No.	Particulars	Figures for 3 months ended	Figures for preceeding 3 months ended	Figures for corresponding 3 months ended in the previous year	Figures for current period ended	Figures for previous period ended
		31-Mar-20	31-Dec-19	31-Mar-19	31-Mar-20	31-Mar-19
		Audited	Unaudited	Audited	Audited	Audited
I	Revenue from Operations	63.00	12.50	30.00	98.76	59.12
II	Other Income	0.00	0.00	0.00	0.00	0.00
III	<b>Total Income (I + II)</b>	<b>63.00</b>	<b>12.50</b>	<b>30.00</b>	<b>98.76</b>	<b>59.12</b>
IV	<b>Expenses:</b>					
	Cost of Materials Consumed	0.00	0.00	0.00	0.00	0.00
	Purchases of Stock in Trade	0.00	4.68	3.98	14.68	32.75
	Changes in Inventories of finished goods, work-in-progress and stock in trade	0.00	0.00	0.00	0.00	0.00
	Employee benefits Expense	1.83	2.27	15.59	13.06	20.80
	Finance Costs	0.00	0.01	0.01	0.12	0.04
	Depreciation & amortisation expense	0.04	0.04	0.01	0.17	0.04
	Other Expenses	63.33	3.66	14.34	69.16	23.74
	<b>Total Expenses (IV)</b>	<b>65.20</b>	<b>10.66</b>	<b>33.93</b>	<b>97.19</b>	<b>77.37</b>
V	<b>Profit / (loss) before exceptional items and tax (III-IV)</b>	<b>-2.20</b>	<b>1.84</b>	<b>-3.93</b>	<b>1.57</b>	<b>-18.25</b>
VI	Exceptional Items	3.06	0.00	17.11	3.06	17.11
VII	<b>Profit / (loss) before tax (V-VI)</b>	<b>0.86</b>	<b>1.84</b>	<b>13.18</b>	<b>4.63</b>	<b>-1.14</b>
VIII	Tax Expense:					
	(1) Current tax	1.45	0.00	0.00	1.45	0.00
	(2) Deferred tax	0.03	0.00	0.00	0.03	0.00
IX	<b>Profit (Loss) for the period from continuing operations (VII-VIII)</b>	<b>-0.62</b>	<b>1.84</b>	<b>13.18</b>	<b>3.15</b>	<b>-1.14</b>
X	Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00
XI	Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00
XII	<b>Profit/(loss) from Discontinuing operations (after tax )(X-XI)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
XIII	<b>Profit / (Loss) for the period (IX+XII)</b>	<b>-0.62</b>	<b>1.84</b>	<b>13.18</b>	<b>3.15</b>	<b>-1.14</b>
XIV	Other comprehensive income					
	A (i) Items that will not be reclassified to profit or loss					
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
	B (i) Items that will be reclassified to profit or loss					
	(ii) Income tax relating to items that will be reclassified to profit or loss					
XV	<b>Total comprehensive income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period)</b>	<b>-0.62</b>	<b>1.84</b>	<b>13.18</b>	<b>3.15</b>	<b>-1.14</b>
XVI	Earnings per equity share (for continuing operation):					
	(1) Basic	0.00	0.03	0.00	0.06	0.00
	(2) Diluted	0.00	0.03	0.00	0.06	0.00
XVII	Earnings per equity share (for discontinued operation):					
	(1) Basic					
	(2) Diluted	0.00	0.00	0.00	0.06	0.00
XVIII	Earnings per equity share (for discontinued & continuing operation):					
	(1) Basic	0.00	0.03	0.00	0.06	0.00
	(2) Diluted	0.00	0.03	0.00	0.06	0.00
	<b>NOTES:</b>					
1	The above Results have been reviewed by the Audit Committee and taken on Record by the Board of Directors at its meeting held today.					
2	The Segment - wise details are not applicable to the Company as the Company has no segments.					
3	The results are Ind-AS compliant however, the previous year figures are not subject to limit review or audit. However the management has exercised necessary due - diligence to ensure that the Financial Results provide a true and fair view of its affairs.					
4	Previous period's figures have been reclassified / regrouped, wherever necessary.					

For Rubra Medicaments Limited

Place: Mumbai  
Date:- August 28,2020

Abha Kapoor  
Director (Finance) & CFO  
DIN: 02799429

**RUBRA MEDICAMENTS LIMITED**

*(Rs. in Lakhs)*

**STATEMENT OF ASSETS AND LIABILITIES**

	Particulars	Figures as at the end of	Figures as at the end of the
		current reporting period	previous reporting period
		31-Mar-20	31-Mar-19
		Audited	Audited
	<b>ASSETS</b>		
<b>1</b>	<b>Non-current assets</b>		
	(a) Property, plant and equipment	1.52	1.69
	(b) Capital work-in-progress	-	-
	(c) Investment property	-	-
	(d) Goodwill	-	-
	(e) Other intangible assets	-	-
	(f) Intangible assets under development	-	-
	(g) Biological assets other than bearer plants	-	-
	(h) Financial Assets		
	(i) Investments	-	-
	(ii) Trade receivables	-	-
	(iii) Loans	-	-
	(iv) Others (to be specified) - Advances	-	-
	(i) Deferred tax assets (net)	-	-
	(j) Other non-current assets	-	-
	<b>Total non-current assets</b>	<b>1.52</b>	<b>1.69</b>
<b>2</b>	<b>Current assets</b>		
	(a) Inventories	-	-
	(b) Financial Assets		
	(i) Investments	-	-
	(ii) Trade receivables	29.00	29.40
	(iii) Cash and cash equivalents	0.05	13.79
	(iv) Bank balances other than (iii) above	0.03	0.21
	(v) Loans	41.51	22.35
	(vi) Others to be specified	-	-
	(c) Current tax assets (net)	-	-
	(d) Other current assets	3.20	2.37
	<b>Total current assets</b>	<b>73.79</b>	<b>68.12</b>
	<b>Total assets</b>	<b>75.31</b>	<b>69.81</b>
<b>1</b>	<b>EQUITY AND LIABILITIES</b>		
	<b>Equity</b>		
	(a) Equity share capital	546.83	546.83
	(b) Other equity	-485.63	-488.79
	<b>Total equity</b>	<b>61.20</b>	<b>58.04</b>
	<b>LIABILITIES</b>		
<b>2</b>	<b>Non-current liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	-	-
	(ii) Trade payables	-	-
	(iii) Other financial liabilities (other than those specified in item (b), to be specified)	-	-
	(b) Provisions	-	-
	(c) Deferred tax liabilities (net)	-	-
	(d) Other non-current liabilities	-	-
	<b>Total non-current liabilities</b>	<b>-</b>	<b>-</b>
	<b>Current liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	-	-
	(ii) Trade payables	-	5.95
	(iii) Other financial liabilities (other than those specified in item (b))	-	-
	(b) Other current liabilities		
	(c) Provisions, current	14.11	5.82
	(d) Current tax liabilities (Net)	-	-
	<b>Total current liabilities</b>	<b>14.11</b>	<b>11.77</b>
	<b>Total liabilities</b>	<b>14.11</b>	<b>11.77</b>
	<b>Total Equity and Liabilities</b>	<b>75.31</b>	<b>69.81</b>